A physiologically based pharmacokinetic model of zidovudine (AZT) in the mouse: model development and scale-up to humans.
After having been used in treating HIV infection for a decade, zidovudine (AZT) continues to be an essential component of antiretroviral regimens. Because antiviral responses and toxicity of AZT seem to be related to cells in specific target tissues, being able to understand and predict the distribution of AZT into different pharmacologically and toxicologically relevant tissues is therefore critically important to improving the efficacy and minimizing the toxicity of AZT therapy. This study was designed to develop a physiologically based pharmacokinetic model to help describe and predict the time course of AZT levels in different tissues. The model was developed in the mouse and then scaled up to predict human situations.
Chow
H H
HH
Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson 85721, USA.
D000818:Animals; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D015215:Zidovudine / Q000493:pharmacokinetics*
D019380:Anti-HIV Agents; D015215:Zidovudine